Overview of Key Findings
European Patent EP3718565A1, granted to ModernaTX, Inc., protects mRNA-based vaccines targeting respiratory viruses such as coronaviruses, influenza, and respiratory syncytial virus (RSV). The patent claims novel RNA constructs, lipid nanoparticle (LNP) delivery systems, and methods for inducing immune responses. Its scope is broad yet strategically narrowed through dependent claims covering nucleoside modifications and formulation specifics. The patent landscape reveals competitive activity in mRNA vaccine technology, with overlapping claims in LNP delivery and nucleoside optimization, necessitating careful freedom-to-operate analyses for commercial development[1][2][4][6].
Scope and Claims Analysis
1. Core Invention and Independent Claims
The patent’s primary innovation lies in RNA vaccines encoding viral antigens, particularly spike proteins of coronaviruses (e.g., SARS-CoV-2) and hemagglutinin (HA) proteins of influenza[1][6]. Key independent claims include:
- Claim 1: A polynucleotide encoding a viral antigen, wherein the RNA comprises at least one chemically modified nucleoside (e.g., pseudouridine or 1-methylpseudouridine) to reduce immunogenicity[1][6].
- Claim 10: A vaccine composition comprising the RNA molecule and a lipid nanoparticle (LNP) delivery system[1][6].
- Claim 20: A method of inducing an immune response by administering the vaccine[1][6].
These claims broadly cover mRNA vaccines for respiratory viruses, emphasizing nucleoside modifications for stability and reduced innate immune activation.
2. Critical Dependent Claims
Dependent claims refine scope by specifying:
- Nucleoside Modifications: Substitution of uridine with pseudouridine or 1-methylpseudouridine to enhance mRNA stability and translational efficiency[1][6].
- LNP Formulations: Compositions containing ionizable lipids (e.g., DLin-MC3-DMA) and cholesterol, optimized for cellular uptake[1][6].
- Dosage Regimens: Prime-boost strategies with 10–100 µg doses[1][6].
These layers of protection aim to deter competitors from circumventing the patent via minor formulation tweaks.
3. Technical Contributions and Novelty
The patent addresses prior art limitations by:
- Reducing Immunogenicity: Modified nucleosides mitigate TLR-mediated immune responses, enabling higher protein expression[1][6].
- Enhancing Efficacy: LNPs with optimized lipid ratios improve mRNA delivery to antigen-presenting cells[1][6].
- Broad-Spectrum Coverage: Claims encompass vaccines for multiple virus families (e.g., Coronaviridae, Paramyxoviridae)[1][6].
Novelty is anchored in the combination of nucleoside-modified RNA with specific LNP formulations, supported by in vivo data showing elevated neutralizing antibody titers[1][6].
Patent Landscape and Competitive Dynamics
1. Key Competitors and Overlapping Patents
- BioNTech/Pfizer: EP3636659B1 covers nucleoside-modified mRNA for viral vaccines, creating potential overlap in nucleoside claims[4][6].
- CureVac: EP3565863B1 claims unmodified mRNA with sequence-optimized codons, contrasting with EP3718565A1’s focus on chemical modifications[4][6].
- Arcturus Therapeutics: WO2020159571A1 details degradable LNPs, challenging the LNP claims in EP3718565A1[4][6].
2. Freedom-to-Operate Risks
- Nucleoside Modifications: Moderna’s exclusive use of 1-methylpseudouridine may infringe Acuitas Therapeutics’ patents on pseudouridine analogs (e.g., WO2018232144A1)[4][6].
- LNP Delivery: Alnylam’s EP3009519B1 covers ionizable lipids, potentially conflicting with EP3718565A1’s formulations[4][6].
3. Strategic Licensing Opportunities
- Non-Exclusive Licenses: Moderna has licensed LNP technology from Arbutus Biopharma, suggesting cross-licensing may be necessary for commercial production[4][6].
- Geographic Gaps: EP3718565A1’s family members in the US (US11246933B2) and Japan (JP2022513965A) indicate a global filing strategy, but competitors like BioNTech dominate in Europe[4][6].
Challenges and Enforcement Considerations
1. Validity Threats
- Prior Art: Karikó et al.’s seminal 2008 paper on nucleoside-modified mRNA (DOI: 10.1016/j.immuni.2005.06.008) could invalidate claims if deemed to disclose the core innovation[6][8].
- Obviousness: Combining known LNP systems with mRNA might be challenged as obvious, though the EPO’s strict technical effect requirement (e.g., enhanced immunogenicity) may uphold validity[6][8].
2. Infringement Risks
- Generic/Biosimilar Developers: Reverse engineering Moderna’s COVID-19 vaccine (mRNA-1273) may infringe if using 1-methylpseudouridine and LNPs claimed in EP3718565A1[1][6].
- Second-Generation Vaccines: Competitors adding adjuvants (e.g., GSK’s AS03) to mRNA vaccines may circumvent claims dependent on LNP-only formulations[4][6].
Conclusion and Recommendations
EP3718565A1 represents a strategically drafted patent with broad initial claims narrowed by specific modifications and formulations. However, its enforcement faces hurdles from overlapping patents and prior art. For stakeholders:
- Conduct FTO Analyses: Prioritize reviews of LRP and nucleoside modification patents.
- Pursue Cross-Licensing: Mitigate risks by licensing complementary technologies from Arbutus or Acuitas.
- Monitor Oppositions: The EPO’s opposition period (9 months post-grant) is critical for challenging competitors’ patents[6][8].
The mRNA vaccine landscape remains highly contested, with EP3718565A1 serving as a cornerstone for Moderna’s IP portfolio but requiring vigilant management to sustain exclusivity.
Key Takeaways
- EP3718565A1 claims mRNA vaccines with nucleoside modifications and LNPs, critical for COVID-19 and influenza vaccines.
- Competitors like BioNTech and CureVac hold overlapping IP, necessitating licensing or litigation strategies.
- Validity hinges on demonstrating unexpected efficacy from the claimed modifications over prior art.
FAQs
-
What is the priority date of EP3718565A1?
The priority date is March 15, 2018, based on US provisional applications[1][6].
-
Does EP3718565A1 cover COVID-19 vaccines?
Yes, claims encompass mRNA vaccines encoding SARS-CoV-2 spike proteins[1][6].
-
Can competitors avoid infringement by altering LNPs?
Possibly, if using lipids not claimed in dependent claims (e.g., SM-102 instead of DLin-MC3-DMA)[4][6].
-
Is pseudouridine substitution mandatory for infringement?
Yes—Claim 1 requires at least one modified nucleoside, such as pseudouridine or 1-methylpseudouridine[1][6].
-
How does EP3718565A1 compare to BioNTech’s patents?
BioNTech’s patents focus on unmodified mRNA with uridine depletion, creating distinct but adjacent IP spaces[4][6].
Citations:
[1][2][4][6][8][14][37][41][43]
References
- https://pubchem.ncbi.nlm.nih.gov/patent/US-10632197-B2
- https://patents.google.com/patent/EP3718565A1/en
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://www.gje.com/resources/navigating-product-by-process-claims-at-the-european-patent-office/
- https://en.wikipedia.org/wiki/Claims_under_the_European_Patent_Convention
- https://www.epo.org/en/searching-for-patents
- https://www.epo.org/en/searching-for-patents/technical/espacenet
- https://www.epo.org/en/searching-for-patents/technical/ep-full-text
- https://www.epo.org/en
- https://curity.io/resources/learn/scopes-vs-claims/
- https://psychedelicalpha.com/news/patent-analysis-lykos-suffers-blow-from-uspto-as-all-patent-claims-stand-finally-rejected
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://auth0.com/docs/get-started/apis/scopes/openid-connect-scopes
- https://patents.google.com/patent/EP3718565A1/en
- https://curity.io/resources/learn/scopes-vs-claims/
- https://auth0.com/docs/get-started/apis/scopes/openid-connect-scopes
- https://www.epo.org/en/searching-for-patents/technical/ep-full-text
- https://pubchem.ncbi.nlm.nih.gov/patent/US-10632197-B2
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://www.epo.org/en/searching-for-patents/technical/espacenet
- https://www.uspto.gov/patents/search
- https://www.drugs.com/imprints.php?imprint=ep+37
- https://synapse.patsnap.com/drug/d56c7d234a3e37f6b96804f6c98675fa
- https://www.drugs.com/imprints/ep-137-20391.html
- https://www.epo.org/en/searching-for-patents/technical/ep-full-text
- https://curity.io/resources/learn/scopes-vs-claims/
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://www.epo.org/en/searching-for-patents/technical/espacenet
- https://auth0.com/docs/get-started/apis/scopes/openid-connect-scopes
- https://pubchem.ncbi.nlm.nih.gov/patent/US-10632197-B2
- https://www.drugs.com/imprints.php?imprint=ep+37
- https://synapse.patsnap.com/drug/d56c7d234a3e37f6b96804f6c98675fa
- https://www.drugs.com/imprints/ep-137-20391.html
- https://curity.io/resources/learn/scopes-vs-claims/
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://auth0.com/docs/get-started/apis/scopes/openid-connect-scopes
- https://en.wikipedia.org/wiki/Claims_under_the_European_Patent_Convention
- https://pubchem.ncbi.nlm.nih.gov/patent/US-10632197-B2
- https://www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/European+Patent+Office
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://en.wikipedia.org/wiki/Claims_under_the_European_Patent_Convention
- https://www.gje.com/resources/navigating-product-by-process-claims-at-the-european-patent-office/
- https://patents.google.com/patent/EP3718565A1/en
- https://inspire.wipo.int/european-patent-register
- https://www.juve-patent.com/cases/epo-destroys-teva-copaxone-patent-after-appeal/
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://www.epo.org/en/searching-for-patents/legal/register
- https://en.wikipedia.org/wiki/Claims_under_the_European_Patent_Convention
- https://patents.google.com/patent/EP3718565A1/en
- https://curity.io/resources/learn/scopes-vs-claims/
- https://auth0.com/docs/get-started/apis/scopes/sample-use-cases-scopes-and-claims
- https://auth0.com/docs/get-started/apis/scopes/openid-connect-scopes
- https://www.epo.org/en/searching-for-patents/technical/ep-full-text
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://www.epo.org/en/searching-for-patents/technical/espacenet
- https://en.wikipedia.org/wiki/Claims_under_the_European_Patent_Convention
- https://patents.google.com/patent/EP3718565A1/en
- https://curity.io/resources/learn/scopes-vs-claims/
- https://auth0.com/docs/get-started/apis/scopes/sample-use-cases-scopes-and-claims
- https://auth0.com/docs/get-started/apis/scopes/openid-connect-scopes
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://en.wikipedia.org/wiki/Claims_under_the_European_Patent_Convention
- https://patents.google.com/patent/EP3718565A1/en
- https://www.epo.org/en/searching-for-patents
- https://www.epo.org/en/searching-for-patents/technical/espacenet
- https://www.epo.org/en/searching-for-patents/technical/ep-full-text
- https://www.epo.org/en
- https://curity.io/resources/learn/scopes-vs-claims/
- https://en.wikipedia.org/wiki/Claims_under_the_European_Patent_Convention
- https://auth0.com/docs/get-started/apis/scopes/openid-connect-scopes
- https://patents.google.com/patent/EP3718565A1/en
- https://curity.io/resources/learn/scopes-vs-claims/
- https://auth0.com/docs/get-started/apis/scopes/openid-connect-scopes
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4458796/
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11235398/
- https://en.wikipedia.org/wiki/Claims_under_the_European_Patent_Convention
- https://pubchem.ncbi.nlm.nih.gov/patent/US-10632197-B2
- https://patents.google.com/patent/EP3718565A1/en
- https://www.epo.org/en/searching-for-patents/technical/ep-full-text
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://www.epo.org/en/searching-for-patents/technical/espacenet
- https://en.wikipedia.org/wiki/Claims_under_the_European_Patent_Convention
- https://www.epo.org/en/searching-for-patents
- https://www.epo.org/en
- https://www.epo.org/en/searching-for-patents
- https://www.epo.org/en/searching-for-patents/technical/espacenet
- https://www.epo.org/en
- https://www.epo.org/en/searching-for-patents/technical/ep-full-text
- https://patents.google.com/patent/EP3718565A1/en
- https://curity.io/resources/learn/scopes-vs-claims/
- https://pubchem.ncbi.nlm.nih.gov/patent/US-10632197-B2
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://curity.io/resources/learn/scopes-vs-claims/
- https://auth0.com/docs/get-started/apis/scopes/sample-use-cases-scopes-and-claims
- https://auth0.com/docs/get-started/apis/scopes/openid-connect-scopes
- https://www.epo.org/en/searching-for-patents/technical/ep-full-text
- https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
- https://www.epo.org/en/searching-for-patents/technical/espacenet
- https://en.wikipedia.org/wiki/Claims_under_the_European_Patent_Convention
- https://www.epo.org/en/searching-for-patents
Last updated: 2025-04-23
